Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma

American Journal of Hematology

Volumn 92, Issue 1, 2017, Pages E11-E13

  Yu, Hui ^a   Sotillo, Elena ^a   Harrington, Colleen ^a,b   Wertheim, Gerald ^a   Paessler, Michele ^a   Maude, Shannon L ^a   Rheingold, Susan R ^a   Grupp, Stephan A ^a   Thomas Tikhonenko, Andrei ^a,b   Pillai, Vinodh ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MEMBRANE ANTIGEN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; TUMOR ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CHILD; COUGHING; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LETTER; LYMPHATIC LEUKEMIA; MEDIASTINUM CANCER; MEDIASTINUM MASS; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SCHOOL CHILD; TACHYCARDIA; DIFFUSE LARGE B CELL LYMPHOMA; IMMUNOTHERAPY; MEDIASTINUM TUMOR; METABOLISM;

ANTIGENS, NEOPLASM; CHILD; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDIASTINAL NEOPLASMS;

EID: 85005949865     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24594     Document Type: Letter

References (8)

1. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:1394–1402.
2. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625–2635.
3. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–549.
4. de Miranda NF, Peng R, Georgiou K, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med 2013;210:1729–1742.
5. Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, et al. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treat Rev 2015; 41: 680–689.
6. Sotillo E, Barrett DM, Black KL, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 2015;5:1282–1295.
7. Evans AG, Rothberg PG, Burack WR, et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol 2015;171:205–209.
8. Jacoby E, Nguyen SM, Fountaine TJ, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 2016;7:12320.